Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL3728317 | 0.97 | LMNA (0.55) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL8981699 | 0.95 | LMNA (0.52) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL8915044 | 0.95 | LMNA (0.52) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL6257976 | 0.95 | TSHR (0.65) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL1549759 | 0.95 | TSHR (0.65) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL10941851 | 0.95 | TSHR (0.65) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL2990240 | 0.95 | TSHR (0.65) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL18640410 | 0.95 | TSHR (0.65) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL80497 | 0.95 | TSHR (0.65) | LMNATSHRALOX12ACHEPCSK9 | |
| Toluene SCHEMBL27455870 | 0.95 | TSHR (0.65) | LMNATSHRALOX12ACHEPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4160084-A | Method for the separation of antibiotic macrolides | MERCK & CO., INC. (US) | 1979-07-03 | — | — | US | claimed |
| US-10752650-B2 | Sophorolipid compound and composition comprising same | SARAYA CO., LTD. (JP) | 2020-08-25 | — | — | US | disclosed |
| CN-1951427-A | Quality control method of a pharmaceutical composition | BEIJING QI YUAN YI PHARM RES (CN) | 2007-04-25 | — | — | CN | disclosed |
| CN-1951417-A | Quality control method of a pharmaceutical composition | BEIJING QI YUAN YI PHARM RES (CN) | 2007-04-25 | — | — | CN | disclosed |
| CN-1077892-C | Oxazolone derivatives and their use as anti-helicobacter pylori agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-16 | — | — | CN | disclosed |
| CN-1230958-A | Oxazolone derivatives and their use as anti-helicobacter pylori agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-10-06 | — | — | CN | disclosed |
| US-5789520-A | POLYAMIDOAMINE CURING AGENT FOR EPOXY RESINS | MITSUI CHEMICALS, INC. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0409399-B1 | 3-keto HMG-COA reductase inhibitors | MERCK & CO INC (US) | 1996-03-13 | — | — | EP | disclosed |
| US-5494893-A | ANTITUMOR AGENTS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0331250-B1 | Antihypercholesterolemic agents | MERCK & CO INC (US) | 1994-04-13 | — | — | EP | disclosed |
| US-RE32006-E | ANTIPARASITIC, ANTHELMINTIC, INSECTICIDAL AND ACARICIDAL AGENTS | MERCK & CO., INC. (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0109811-A2 | Bryozoan antibiotics | ARIZONA BOARD OF REGENTS (US) | 1984-05-30 | — | — | EP | disclosed |
| US-4412991-A | ANTHELMINTICS, MITICIDES, INSECTICIDES, NEMATOCIDES, ANTIBIOTICS | MERCK & CO., INC. (US) | 1983-11-01 | — | — | US | disclosed |
| US-4387242-A | Hypocholesterolemic fermentation products and process of preparation | MERCK & CO., INC. (US) | 1983-06-07 | — | — | US | disclosed |
| US-4376863-A | ANTICHOLESTEROL, ANTILIPEMIC AGENTS, FUNGICIDES | MERCK & CO., INC. (US) | 1983-03-15 | — | — | US | disclosed |
| EP-0073660-A1 | Novel derivatives of C-076 compounds, their production and use, and compositions containing them | MERCK & CO. INC. (US) | 1983-03-09 | — | — | EP | disclosed |
| US-4201861-A | Acyl derivatives of C-076 compounds | MERCK & CO., INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4199569-A | ANTHELMINTIC MACROLIDES | MERCK & CO., INC. (US) | 1980-04-22 | — | — | US | disclosed |
| US-4171314-A | INSECTICIDES, MITICIDES, PARASITICIDES, ANTHELMINTICS | MERCK & CO., INC. (US) | 1979-10-16 | — | — | US | disclosed |
| US-4160084-A | Method for the separation of antibiotic macrolides | MERCK & CO., INC. (US) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752650-B2 | Sophorolipid compound and composition comprising same | MGLL, LPL, FADS1 | LMNA 1417/4885TSHR 2158/4885ALOX12 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.